This move is archived. Current quotes and coverage live on the stock page.
Get APTX alerts:
Apotex Health Corp's stock surged over 6% in a single trading day, marking a significant milestone for the company.
In a remarkable showing, Apotex Health Corp (APTX.TO) saw its stock price rise by 6.15% in the last session, closing at CA$37.79. This upward movement reflects growing investor confidence and potential positive sentiment in the pharmaceutical sector.
Advertisement
Apotex Health Corp
APTX.TO
APTX.TO
Apotex Health Corp
WealthAwesomeMarket cap
$7.67B
52W high
$40.18
52W low
$26.05
1W change
-3.56%
Analyst Price Targets
Based on analyst covering APTX
Wall Street analysts forecast APTX stock price to rise 25.1% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$41.34
+25.1% Upside
Current Price
C$33.06
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on APTX's historical volatility
30-Day Vol
44.7%
Annualized
90-Day Vol
49.1%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$39.52
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$35.09 | C$30.08 – C$40.93 |
| 60 trading days | C$37.24 | C$29.95 – C$46.31 |
| 90 trading days | C$39.52 | C$30.27 – C$51.61 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: For Canadian investors, Apotex's recent performance indicates a potentially lucrative opportunity, especially considering its recent strategic moves and product approvals.
6.15% Surge in One Day
Apotex's stock gained CA$2.19 in just one trading session, reflecting strong investor interest and market confidence.
Bull case
The stock's rise is linked to Apotex's recent strategic deal with Cumberland Pharmaceuticals, which could strengthen its market position and growth prospects. Plus, the approval of SEVMIA™, a generic semaglutide for weight management, puts Apotex in a strong position within a growing market.
Bear case
Even with this positive momentum, investors should tread carefully. The pharmaceutical industry can be unpredictable, and any setbacks in product approvals or increased competition might hurt stock performance.
Recent Developments Fueling Growth
Advertisement
Apotex recently completed a strategic transaction with Cumberland Pharmaceuticals, integrating their U.S. branded businesses. This move is expected to boost Apotex's market presence and product offerings, contributing to the stock's positive performance.
Product Approvals Boost Investor Confidence
The recent approval of SEVMIA™ by Health Canada is a key moment for Apotex, positioning the company as a leader in the market for chronic weight management solutions. Such approvals not only expand their product line but also attract investor interest.
Market Outlook and Future Considerations
While the current surge is promising, investors should stay alert. The pharmaceutical sector comes with its challenges, including regulatory hurdles and market competition. Keeping an eye on Apotex's future product launches and market strategies will be crucial for informed investing.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
